問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital

Division of Family Medicine

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間:2024-02-21

黃維俊
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

15Cases

2025-10-01 - 2028-12-31

Active
A phase 2b, randomized, double-blind, placebo-controlled, parallel, multiple-dose trial was conducted to evaluate the efficacy, safety, and pharmacokinetics of AZD0292 in patients aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa grafts.
  • Condition/Disease

    In NCFBE and chronic PsA transfer subjects, the effect of AZD0292 IV every 4 weeks (Q4W) compared with placebo on the incidence of moderate to severe acute lung exacerbations was evaluated.

  • Test Drug

    AZD0292

Participate Sites
7Sites

Recruiting7Sites

2025-12-11 - 2031-06-30

Phase III

Not yet recruiting
A phase 3, randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy and safety of GB-0895 adjunctive therapy in adults and adolescents with severe, poorly controlled asthma.
  • Condition/Disease

    Adults and adolescents with severely uncontrolled asthma

  • Test Drug

    GB-0895

Participate Sites
6Sites

Recruiting6Sites

2024-05-31 - 2027-05-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-01-31 - 2028-01-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2026-01-29 - 2031-11-15

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-01-22 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2026-01-02 - 2030-01-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-10-01 - 2027-10-01

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-05-16 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2026-05-01 - 2027-07-28

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2